- cetylpyridinium chloride
GSL: General Sales List
This information is intended for use by health professionals
Adult Meltus Chesty Coughs Sugar & Colour Free
Lemsip Cough for Mucus Cough & Catarrh 100mg/2.5mg/5ml Oral Solution
Adult Cough Linctus Sugar & Colour Free contains per 5 ml dose:
Guaiphenesin 100 mg
Cetylpyridinium chloride 2.5 mg
Also contains Liquid Sorbitol (E420), Glycerol and Ethanol.
For full list of excipients, see section 6.1.
Clear, pale straw coloured liquid
For the symptomatic relief of acute chesty coughs and catarrh associated with influenza, colds and mild throat infections.
Not recommended for children under 12 years of age.
Glass bottle - Adults and children 12 years and over:
One or two 5 ml spoonfuls to be taken and swallowed slowly every three or four hours.
PETE plastic bottle - Adults and children 12 years and over:
5 ml (fill the measure cup to 5 ml) or 10 ml (fill measure cup to 10 ml). To be taken 3 or 4 times daily. Rinse the measure cup after use.
Hypersensitivity to the active substance or to any of the excipients
Ask your doctor before use if you suffer from a chronic cough, if you have asthma or are suffering from an acute asthma attack.
Stop use and ask a healthcare professional if your cough lasts for more than 5 days, comes back, or is accompanied by a fever, rash, or persistent headache.
Do not take with a cough suppressant.
Not suitable for children under 12 years of age.
This medicinal product contains 9.0% v/v of ethanol i.e. each 5ml dose contains up to 0.364 mg of alcohol, equivalent to 9ml of beer, or 3.75ml of wine. This can be harmful for those suffering from alcoholism. This should be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease, or epilepsy.
Can cause transient abnormality in platelet aggregation patterns determined one hour after ingestion.
If urine is collected within 24 hours of a dose of the medicinal product, a metabolite of guaifenesin may cause a colour interference with laboratory determinations of urinary 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).
No known contraindications.
There is limited amount of data from the use of Guaifenesin in pregnant women.
There is no information on use in lactation.
Therefore, it should not be used during pregnancy or breastfeeding unless advised by a doctor or a pharmacist.
The following side effects may be associated with the use of Guaifenesin:
Gastro-intestinal disorders: Nausea and vomiting.
Immune system disorders: Hypersensitivity reactions
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Very large doses may cause nausea and vomiting. It is however, rapidly metabolised and excreted in the urine. The patient should be kept under observation and treated symptomatically.
Pharmacotherapeutic group: Cough and cold preparations, Expectorants;
ATC Code: R05CA10
A cough linctus containing an expectorant and an oral antiseptic in a sugar and colour free base. The expectorant, guaifenesin, is employed to produce a thinning of mucous secretions increasing the volume of mucus that can be expelled by mucociliary action due to a reduction in the adhesiveness and viscosity of tenacious sputum. Thus providing relief to bronchial catarrh.
The antiseptic, cetylpyridinium chloride, is used for the treatment of superficial mouth infections and has an antibacterial activity on Gram-positive bacteria.
Guaifenesin is readily absorbed from the gastrointestinal tract after oral administration and rapidly metabolised by oxidation to beta-(2-methoxyphenoxy)-lactic acid. Within 3 hours, approximately 40% of a single dose is excreted in the urine as this metabolite. The half-life in plasma is approximately 1 hour.
Guaifenesin may increase the absorption rate of paracetamol, however the clinical relevance of this is unknown
No pharmacokinetic data are available for cetylpyridinium chloride.
There are no preclinical safety data of relevance to the consumer.
Liquid Sorbitol Non-Crystallising (E420)
Glass bottle - Five years unopened.
Transparent blue plastic PETE bottle – Two years unopened.
Transparent green plastic PETE bottle – Two years unopened.
Do not store above 25°C.
Do not refrigerate or freeze.
Amber glass sirop bottle fitted with tamper evident polypropylene cap with expanded polyethylene liner, packed in printed cartons containing 100ml of linctus.
Transparent blue plastic PETE bottle (180 ml).
Transparent green plastic PETE bottle (180 ml)
Translucent yellow graduated polypropylene measuring cup.
Reckitt Benckiser Healthcare (UK) Limited
103-105 Bath Road,
25/10/1995 / 14/09/2001
RB Consumer Relations, PO Box 4644, SLOUGH, SL1 0NS, UK
0333 2005 345
0333 2005 345
0333 2005 345